e-learning
resources
Barcelona 2010
Tuesday, 21.09.2010
Management of airway disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Comparative evaluation of desloratadine versus levocetirizine in managing patients with comorbid rhinitis and asthma in the United Kingdom
J. McLaughlin, C. de Moor, G. Reardon, P. Navaratnam (Columbus, United States Of America)
Source:
Annual Congress 2010 - Management of airway disease
Session:
Management of airway disease
Session type:
Thematic Poster Session
Number:
4573
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. McLaughlin, C. de Moor, G. Reardon, P. Navaratnam (Columbus, United States Of America). Comparative evaluation of desloratadine versus levocetirizine in managing patients with comorbid rhinitis and asthma in the United Kingdom. Eur Respir J 2010; 36: Suppl. 54, 4573
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Economic evaluation of beclomethasone/formoterol versus budesonide/formoterol in the treatment of patient with moderate-severe asthma in Spain
Source: Annual Congress 2008 - Impact of patient education on cost-effectiveness of treatment
Year: 2008
Efficacy of montelukast in Indian patients having chronic persistent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 372s
Year: 2003
Efficacy of cetirizine and pseudoephedrine in school children with seasonal allergic rhinitis and mild asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 526s
Year: 2002
Effects of loratadine and its generic on symptoms of asthma and rhinitis
Source: Annual Congress 2008 - Allergy and immunology of asthma and beyond
Year: 2008
Efficacy of montelukast in patients with concomitan persistent allergic rhinitis and asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 663s
Year: 2006
Efficacy and safety of ciclesonide in the treatment of patients with persistent allergic or non-allergic asthma
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012
Cost-effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: adaptation of INNOVATE and ETOPA data to the Netherlands
Source: Annual Congress 2007 - Cost-effectiveness in diagnosis, therapy and care
Year: 2007
Efficacy of the using budesonide/formoterol in patients with bronchial asthma (BA): the study of routine clinical practice
Source: Eur Respir J 2006; 28: Suppl. 50, 499s
Year: 2006
Safety of once-daily QMF149 in patients with persistent asthma
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012
Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Effect of omalizumab treatment on allergic comorbidities in patients with severe allergic asthma – real life experience from Czech Anti-IgE Registry
Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside
Year: 2017
Safety and efficacy of omalizumab in children with allergic asthma
Source: Annual Congress 2011 - Treating childhood asthma
Year: 2011
Patients’ perception of allergic asthma and their compliance to omalizumab in an Italian clinical setting
Source: International Congress 2017 – Asthma management
Year: 2017
Pharmacoeconomic analysis of beclomethasone/formoterol versus fluticasone/salmeterol in the treatment of moderate-severe asthma in Spain
Source: Annual Congress 2008 - Impact of patient education on cost-effectiveness of treatment
Year: 2008
Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Long-term effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Real-life data from 3 UK centres
Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE
Year: 2012
Association between allergic rhinitis and hospital resource use among asthmatic children in Norway
Source: Eur Respir J 2002; 20: Suppl. 38, 335s
Year: 2002
Asthma exacerbations in children receiving montelukast vs. other controllers in Italy
Source: Eur Respir J 2005; 26: Suppl. 49, 618s
Year: 2005
Real-life evaluation of budesonide/formoterol (DuoResp Spiromax) for the management of asthma and COPD in the UK
Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD
Year: 2017
Safety of formoterol in children and adolescents: experience from asthma clinical trials
Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept